Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram + gaboxadol versus escitalopram in major depressive disorder
2008-000506-36Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gaboxadol in major depressive disorder (MDD) (3 arms), sponsored by Lundbeck. Primary endpoint: Change from baseline in MADRS total score at Week 8. Started Sep 2008; status: completed.
02
Drugs
gaboxadol
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-000506-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000506-36.